Linda Kadan has over 15 years of experience in biotech and rare disease sales, with a track record of award-winning achievements and consistently exceeding sales goals. She has extensive relationships within cardiopulmonary, transplant, and other specialized disease areas. Her experience includes successful product launches and business growth in new markets. She is adept at navigating complex healthcare environments in New York City.

1. Linda Kadan
516-978-3499
Kadanl@yahoo.com
HIGHLIGHTS OF QUALIFICATIONS
Award winning sales representative with 15+ year experience in Biotech and Rare Disease.
Independent and entrepreneurial self-starter with documented award winning achievements
within institutional and academic settings. Experienced in parenteral/injectable and
complex delivery systems. Outstanding performance within orphan disease marketplace and
transactional/high pressure environments. Extensive relationships within
cardio/pulmonary/transplant and highly specialized disease states. SPS relationships and
pull-through track record. Extensive product launches with start-ups and first in class
therapies. Highly adept at growing business in new and challenging marketplace.
Outstanding execution in large geographies. Intuitive understanding of business
development and navigating NYC. Excellence and ethical behavior in all business
transactions. Advocate for patient care
2013-Present United Therapeutics-Sr. Institutional Cardiopulmonary Specialist NYC
Q3 16-Ranked #1 North East Region for new starts
Q2 16-Ranked #1 in NorthEast Region for overall 3 year performance
Q1 16 180% to goal achievement
Q2 15 118% to goal
Q2 15 Orenitram- grew Orenitram business in 2 new accounts by 5 totaling 400% growth
Q2 15 Achieved number 1 ranking nationally Orenitram starts
Q3 14 achieved 22 starts vs goal of 18-122% attainment
Q2 14 Launched Orenitram achieved #2 ranking nationally
2010-2013 United Therapeutics-Sr. Cardiopulmonary Specialist-NYC
Q4 13 attained 43 starts –goal was 32
Q1 13 Achieved Black Diamond Ranking-performance 30% above goal
Q4 12 performance-quota 24 achieved 29 Treprostinil starts
Diamond Award of Achievement 2nd
Quarter 2012
Established referral pattern/business relationships between community and PAH Centers
Nominated and completed UT Senior CPS program
Met and exceeded RBD goals for 2011/ 2012/2013
Established relationships with SPS partners and consistent pull-through
Proven track record in formulary wins
2008-2010 Lung Rx (division of United Therapeutics)
Achieved #1 sales ranking nationally for all Pulmonary Specialists
Adcirca fast start award for #1 performance nationally for the Adcirca brand
Achieved #1 ranking rep nationally for Remodulin starts
Lead nation in # of documented Tyvaso starts
Valedictorian Lung Rx sales training
2007-2008 Johnson and Johnson Jansen Institutional Representative Brooklyn)
Injectable sales force achievement of 200% performance quota with 9.75% share change
Institutional ranking of #4 regionally
Education provided to treatment team on injection technique/secured formulary access
2005-2007 CV Therapeutics Cardiovascular/Biotech Account Specialist, Queens/LI
Attained year-end national ranking 8/258, district 1/13, region 1/70
Ranked #1 in district for Ranexa launch, #1 regional ranking, #20 nationally
Consistent Leaders Circle Award Winner
Awarded #1 Sales Person of 2006 for Northeast Region
Solely launched Ranexa; a very complicated molecule and a new paradigm for ischemia
Achieved 200% NRX growth within hospitals and Cath Lab/Cardiac Rehab/CCU/ICU/ER
EDUCATION- BA Pace University